Canada markets open in 20 minutes

InMed Pharmaceuticals Inc. (INM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4900-0.1400 (-8.59%)
At close: 04:00PM EST
1.5500 +0.06 (+4.03%)
Pre-Market: 08:59AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.6300
Open1.6300
Bid1.5000 x 1400
Ask1.6100 x 1100
Day's Range1.4400 - 1.6600
52 Week Range1.2550 - 6.4200
Volume582,537
Avg. Volume3,117,753
Market Cap21.064M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-1.3740
Earnings DateFeb. 09, 2022 - Feb. 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.75
  • GlobeNewswire

    InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference

    VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMed’s management team is scheduled to participate in Cowen’s 4th Annual Cannabis Conference to be held virtually on November 29 – December 1, 2021. Cowen's 4th Annual Cannabis Conference Date: November 29 - December 1, 2021 Management will be available for v

  • ACCESSWIRE

    InMed Pharmaceuticals (INM): Progress Across the Business

    LONDON, UK / ACCESSWIRE / November 17, 2021 / With the recent closing of the BayMedica acquisition, InMed now has a substantially different profile than just a few months ago. The company is now in its commercial stage as BayMedica has been selling cannabichromene (CBC) in bulk.

  • Zacks

    InMed Pharmaceuticals Inc. (INM) Reports Q1 Loss, Lags Revenue Estimates

    InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of 28.57% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?